We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.09 | 1.44% | 76.97 | 76.50 | 76.98 | 76.80 | 75.96 | 76.34 | 4,911,684 | 00:59:15 |
From May 2021 to May 2024
By Jaime Llinares Taboada
AstraZeneca PLC said Monday that its Enhertu cancer treatment achieved positive results at its first phase III head-to-head trial.
The pharmaceutical company said the trial compared Enhertu with trastuzumab emtansine on patients with HER2-positive breast cancer. HER2 protein overexpression is often associated with aggressive disease and a poor prognosis in breast cancer.
An independent committee concluded that the trial met the primary endpoint of progression-free survival, showing improvements for patients with HER2-positive breast cancer.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
(END) Dow Jones Newswires
August 09, 2021 02:35 ET (06:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
